These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29600225)

  • 61. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
    Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT)
    Sakai M; Sohda M; Saito H; Nakazawa N; Ubukata Y; Kuriyama K; Hara K; Sano A; Ogawa H; Yokobori T; Murata K; Noda SE; Ohno T; Shirabe K; Saeki H
    Anticancer Res; 2021 Apr; 41(4):2141-2145. PubMed ID: 33813425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
    Rao S; Starling N; Cunningham D; Sumpter K; Gilligan D; Ruhstaller T; Valladares-Ayerbes M; Wilke H; Archer C; Kurek R; Beadman C; Oates J
    Ann Oncol; 2010 Nov; 21(11):2213-2219. PubMed ID: 20497967
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
    Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
    Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
    [TBL] [Abstract][Full Text] [Related]  

  • 65. DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
    Kim S; Vendrely V; Saint A; André T; Vaflard P; Samalin E; Pernot S; Bouché O; Zubir M; Desrame J; de la Fouchardière C; Smith D; Ghiringhelli F; Vienot A; Jacquin M; Klajer E; Nguyen T; François É; Taieb J; Le Malicot K; Vernerey D; Meurisse A; Borg C
    Exp Hematol Oncol; 2023 Jul; 12(1):63. PubMed ID: 37480095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
    Melcher AA; Mort D; Maughan TS
    Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
    Unek IT; Akman T; Oztop I; Unal OU; Salman T; Yilmaz U
    Gastric Cancer; 2013 Jul; 16(3):428-34. PubMed ID: 23086560
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
    Stouvenot M; Meurisse A; Saint A; Buecher B; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Smith D; Ghiringhelli F; Parzy A; de la Fouchardiere C; Almotlak H; Vienot A; Jacquin M; Taieb J; Nguyen T; Vernerey D; Borg C; Kim S
    Eur J Cancer; 2022 Feb; 162():138-147. PubMed ID: 34995900
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Onal Y; Uzunoglu S; Cicin I
    Mol Clin Oncol; 2015 Sep; 3(5):1160-1164. PubMed ID: 26623070
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
    Kim S; Paget-Bailly S; Messager M; Nguyen T; Mathieu P; Lamfichekh N; Fein F; Fratté S; Cléau D; Lakkis Z; Jary M; Sakek N; Jacquin M; Foubert A; Bonnetain F; Mariette C; Fiteni F; Borg C
    Eur J Surg Oncol; 2017 Jan; 43(1):218-225. PubMed ID: 27425578
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
    Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
    Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
    N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.
    Tomasello G; Valeri N; Ghidini M; Smyth EC; Liguigli W; Toppo L; Mattioli R; Curti A; Hahne JC; Negri FM; Panni S; Ratti M; Lazzarelli S; Gerevini F; Colombi C; Panni A; Rovatti M; Treccani L; Martinotti M; Passalacqua R
    Oncotarget; 2017 Dec; 8(67):111795-111806. PubMed ID: 29340092
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
    Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
    Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer.
    Noronha V; Joshi A; Jandyal S; Jambhekar N; Prabhash K
    Med Oncol; 2014 Sep; 31(9):188. PubMed ID: 25148898
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
    Sun W; Metz JM; Gallagher M; O'Dwyer PJ; Giantonio B; Whittington R; Haller DG
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):621-7. PubMed ID: 20495918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.